Molecular structure of Zoledronic acid, anhydrous, CAS Number: 118072-93-8
Zoledronic acid, anhydrous (CAS 118072-93-8)
See product citations (5)
Alternate Names:
Zoledronate
Application:
Zoledronic acid, anhydrous is a protein kinase C activator with apoptotic effects
CAS Number:
118072-93-8
Purity:
≥98%
Molecular Weight:
272.09
Molecular Formula:
C5H10N2O7P2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Zoledronic acid, anhydrous, also known as zoledronate, is a nitrogen-containing bisphosphonate compound. Zoledronic acid, anhydrous, one of the most potent nitrogen-containing bisphosphonates, induces anti-proliferative and apoptotic effects on multiple myeloma cell lines in vitro by activating protein kinase C. Zoledronic acid, anhydrous also inhibits proliferation of human foetal osteoblastic cell line (hFOB) with an IC50 of 40 μM. In cultures of freshly isolated rabbit and human osteoclasts, zoledronic acid, anhydrous (10-100 μM) induced morphological features similar to apoptosis and Osteoclastogenesis was inhibited with an IC50 of 15 nM by binding to farnesyl diphosphate synthase, an enzyme involved in the synthesis of farnesyl diphosphate necessary for osteoclast function. Furthermore, zoledronic acid, anhydrous has demonstrated the ability to suppress cytokine production, which contributes to inflammation, as well as impede the production of angiogenic factors involved in blood vessel growth.
Zoledronic acid, anhydrous (CAS 118072-93-8) References
- Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. | Sudhoff, H., et al. 2003. Ann Otol Rhinol Laryngol. 112: 780-6. PMID: 14535562
- Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. | Thudi, NK., et al. 2008. Prostate. 68: 1116-25. PMID: 18461562
- Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid. | Lézot, F., et al. 2015. Bone. 73: 51-9. PMID: 25532478
- Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition. | Nagaoka, Y., et al. 2015. J Dent Res. 94: 594-601. PMID: 25535203
- PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology. | Bartlow, CM., et al. 2017. J Orthop Res. 35: 1707-1715. PMID: 27653318
- Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta. | Little, DG., et al. 2017. Bone. 101: 96-103. PMID: 28461254
- PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. | Li, Y., et al. 2018. BMC Cancer. 18: 669. PMID: 29921237
- The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. | Vitellius, C., et al. 2018. Oncotarget. 9: 28069-28082. PMID: 29963262
- Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62P394L mouse model of Paget's disease. | Daroszewska, A., et al. 2018. Dis Model Mech. 11: PMID: 30154079
- Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons. | Vargas-Franco, JW., et al. 2019. Biochem Pharmacol. 168: 133-148. PMID: 31260659
- Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups. | Cubria, MB., et al. 2020. Proc Natl Acad Sci U S A. 117: 12029-12040. PMID: 32404427
- Zoledronic Acid in a Mouse Model of Human Fibrous Dysplasia: Ineffectiveness on Tissue Pathology, Formation of 'Giant Osteoclasts' and Pathogenetic Implications. | Corsi, A., et al. 2020. Calcif Tissue Int. 107: 603-610. PMID: 32875378
- Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner. | Kozutsumi, R., et al. 2022. Calcif Tissue Int. 110: 104-116. PMID: 34363509
- GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. | Chen, J., et al. 2021. Signal Transduct Target Ther. 6: 397. PMID: 34795203
- Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta. | Lee, LR., et al. 2022. Bone. 159: 116378. PMID: 35257929
Inhibitor of:
γ-FR, 2310046A06Rik, 4922505G16Rik, 4930458L03Rik, 4930502E18Rik, 7530416G11Rik, 9230110F15Rik, Akp-6, amelotin, ARL13A, ARPP-21, ASAH3, B9D1, C1orf94, C6orf182_2410017P07Rik, C8orf80, CCDC175, cementum attachment protein, CEMP1, CHM Rab escort protein, CHMP5, CLC-7, Cln1, DIRC2, DSPG3, Dymeclin, EBPBP β, EG668210, Enzyme, FTα, Gm1966, Gm2897, Gm44, H2-Db, HEATR2, HTPAP, ICMT, IDI1, iGb3, KIR3DL1, Lamin A/C, LOC100041261, LOC100041416, LOC100041448, LOC100041471, LOC440330, LOC645733, LOC646836, LOC728861, LOC730210, LST1, MAGE-H1, MAP17, MDP-1, MVK, MYL2, MYL7, NELL1, NPT2, OCIL, OFD1, Olr500, Olr684, Olr766, OSCAR, PGCP, PIG-M, PIG-V, Pin4, PINLYP, PPP1R4, Ppp4r1l, PRG-3, Protein tyrosine phosphatase receptor (PTPR), PTH2 Receptor, PTPκ, PTPDC1, R-ras3, Rab 18, Rab 24, Rab 30, Rab 9A, Rab GTPase (RAB; RAS oncogene), Rab40B, RABAPTIN-5, RAP, RASA4, RASL10B, RASL11B, RASL12, RB3, RCE1, RGL4, Rho D, Rho J, RHOBTB3, RUNX3, S-100A2, SAPCD2, SENP8, Ser/Thr Protein Kinase, SFTPG, SH3TC1, SSXB8, Svs3a, TBC1D2B, TERE1, TMEM138, TMEM223, TPTE, Tsga8, TUSC1, VCY1B, VMA21, WDR17, WDR72, and WFDC1.Activator of:
1110032A03Rik, 1700016D06Rik, 1700019N19Rik, 2010007H12Rik, 4930430D24Rik, ACTR-IC, BBS2, BBS8, BTN3A1, Butyrophilin, C16orf65, C20orf194, CD32-B_Fc γ RIIb, CD38, Cdc14a phosphatase, Cdc37L1, COL10A1, connexin 45, CTGLF1, EG435376, EML5, F5 TCR β, GATA-3, GBP8, GDF-16, GGtase-α, GGTase-Iα, GITRL, Gm600, Gm70, IFITM5, Integrin β6, KIF1C, KKIALRE, Lamin B1, LIN-15A, LIR-7, Ly-49B, Ly-49D, Ly-49J, Ly-49W, Lysozyme, M-CSF, MAGE-C3, MAN2B1, MP1, MTMR3, MTMR5, Myeloid Marker, N-WASP, N4BP2, Nek2, NKHC1, Nore1/RASSF5, NUDT21, OG1, OG2, PCTAIRE-3, PEBP2αA, phostensin, PIG-Q, PKC, PMEPA1, PP6R3, PPM1H, PPP4R4, PR48, PRAMEF8, PSTPIP1, PTPLA, Rab 7L1, Rab L3, Rab L4, RAET1G, RAG-2, RASSF8, RUNX2, SAS-4, SH2D3A, SLC25A33, SOBP, SPR1, SPRYD4, SRBD1, SRSP1, STI1, T-cell receptor Vδ 2, TCIRG1, TIEG2, TRAP, TRAP1, Trav12-1, Trav12-2, Trav17, Trav2, Trav3n-3, uPA, WDR3, WDR42C, and ZIP-kinase.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Zoledronic acid, anhydrous, 25 mg | sc-364663 | 25 mg | $90.00 | |||
Zoledronic acid, anhydrous, 100 mg | sc-364663A | 100 mg | $251.00 |